1 An Interview with Martin Andrews, GSK, on EMA Adaptive Licensing Pilot Program and Early Access schemes
event strap

An Interview with Martin Andrews, GSK, on EMA Adaptive Licensing Pilot Program and Early Access schemes

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Explore whether or not the UK's Early Access to Medicines Scheme is a positive step forward

In March 2014 the UK Early Access to Medicines Scheme was launched, and within two weeks an Adaptive Licencing initiative was also launched by the European Medicines Agency (EMA). These two programmes present new opportunities to enable earlier drug access to the market, giving patients with rare diseases quicker access to potentially life saving drugs.

In this report we speak with Martin Andrews, Senior Vice President Rare Diseases, GSK, about these two schemes and whether they are positive steps forward.

 

Download the report for a 10% discount, and to learn more about Martin's thoughts on:

  • Adaptive Licensing as a positive move forward and how it will develop in the next few years
  • The potential drawbacks to both schemes
  • If enough is being done within the UK and further afield to provide those with rare diseases adequate access to potentially lifesaving drugs
  • Recommendations to enable greater access to drugs for those with rare diseases

Join us in London on 10th July 2014 at the Fast Tracking Orphan Drugs Briefing to learn how these and other new developments will speed up orphan drug market access.
Download this Ebook to gain an exclusive 10% discount. Book now!